Page 27 - 84_04
P. 27
Arantxa Rodriguez-Casado, Adolfo Toledano-Díaz, María-Isabel Álvarez, Adolfo Toledano
peroxisome proliferator-activated receptor: A family GS, Claxton A, et al. Intranasal insulin therapy for
of nuclear receptors role in various diseases. J Adv Alzheimer disease and amnestic mild cognitive
Pharm Technol Res 2011;2(4):236-40. impairment: a pilot clinical trial. Arch Neurol
61. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones 2012;69(1):29-38.
and the promise of insulin sensitization in type 2 77. Freiherr J, Hallschmid M, Frey WH, Brünner YF,
diabetes. Cell Metab 2014;20(4):573-91. Chapman CD, Hölscher Cet al. Intranasal insulin as a
62. Woodcock J, Sharfstein JM, Hamburg M. Regulatory treatment for Alzheimer's disease: a review of basic
action on rosiglitazone by the US Food and Drug research and clinical evidence. CNS Drugs
Administration. N Engl J Med 2010;363(16):1489-91. 2013;27(7):505-14.
63. Hernandez AV, Usmani A, Rajamanickam A, Moheet 78. Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin,
A. Thiazolidinediones and risk of heart failure in other antidiabetic drugs, and risk of Alzheimer's
patients with or at high risk of type 2 diabetes disease: a population-based case-control study. J Am
mellitus: a meta-analysis and meta-regression analysis Geriatr Soc 2012;60(5):916-21.
of placebo-controlled randomized clinical trials. Am J 79. Miller BW, Willett KC, Desilets AR. Rosiglitazone
Cardiovasc Drugs 2011;11(2):115-28. and pioglitazone for the treatment of Alzheimer's
64. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz disease. Ann Pharmacother 2011;45(11):1416-24.
M, Andreelli F. Cellular and molecular mechanisms of 80. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et
metformin: an overview. Clin Sci (Lond) al. Antidiabetic drug metformin (GlucophageR)
2012;122(6):253-70. increases biogenesis of Alzheimer's amyloid peptides
65. Rojas LB, Gomes MB. Metformin: an old but still the via up-regulating BACE1 transcription. Proc Natl
best treatment for T2D. Diabetol Metab Syndr Acad Sci USA 2009;106(10):3907-12.
2013;5(1):6. 81. Geldmacher DS, Fritsch T, McClendon MJ, Landreth
66. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC.. G. A randomized pilot clinical trial of the safety of
Metformin rapidly increases insulin receptor pioglitazone in treatment of patients with Alzheimer
activation in human liver and signals preferentially disease. Arch Neurol 2011;68(1):45-50.
through IRS-2. J Clin Endocrinol Metab 82. Jiang Q, Heneka M, Landreth GE. The role of
2003;88(3):1323-32. peroxisome proliferator-activated receptor-gamma
67. Talbot K, Wang HY. The nature, significance, and (PPARgamma) in Alzheimer's disease: therapeutic
glucagon-like peptide-1 analog treatment of brain implications. CNS Drugs 2008;22(1):1-14
insulin resistance in Alzheimer's disease. Alzheimers 83.. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB,
Dement 2014;10(Suppl 1):S12-25. Craft S, Haynatzki GR. Rosiglitazone attenuates
68. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 learning and memory deficits in Tg2576 Alzheimer
receptor agonists: efficacy and safety in diabetes and mice. Exp Neurol 2006;199(2):265-73.
beyond. Drugs Context 2015;4:212283. 84. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke
69. Finsterer J, Frank M. Repurposed drugs in metabolic A, Dewachter I, Kuiperi C, et al. Acute treatment with
disorders. Curr Top Med Chem 2013;13(18):2386-94. the PPAR? agonist pioglitazone and ibuprofen reduces
70. Shim JS, Liu JO. Recent advances in drug glial inflammation and Abeta1-42 levels in APPV717I
repositioning for the discovery of new anticancer transgenic mice. Brain 2005;128(Pt 6):1442-53.
drugs. Int J Biol Sci 2014;10(7):654-63. 85. Talbot K. Brain insulin resistance in AD and its
71. Corbett A, Williams G, Ballard C. Drug repositioning potential treatment with GLP-1 analogs.
in AD. Front Biosci (Schol Ed) 2015;7:184-8. Neurodegener Dis Manag 2014;4(1):31-40.
72. Ghezzi L, Scarpini E, GalimbertiD. Disease-modifying 86. Campbell JE, Drucker DJ. Pharmacology, physiology,
drugs in AD. Drug Des Devel Ther 2013;7:1471-8. and mechanisms of incretin hormone action. Cell
73. Balsamo S, Willardson JM, Frederico S, Prestes J, Metab 2013;17(6):819-37.
Balsamo DC, Dahan CN et al. Effectiveness of 87. Zhang XZ, Quan Y, Tang GY. Medical genetics-based
exercise on cognitive impairment and Alzheimer's drug repurposing for Alzheimer's disease. Brain Res
disease. Int J Gen Med 2013;6:387-91. Bull 2015;110:26-9.
74. Gillette-Guyonnet S, Secher M, Vellas B. Nutrition 88. McClean PL, Parthsarathy V, Faivre E, Hölscher C.
and neurodegeneration: epidemiological evidence and The diabetes drug liraglutide prevents degenerative
challenges for future research. Br J Clin Pharmacol processes in a mouse model of Alzheimer's disease. J
2013;75(3):738-55. Neurosci 2011;31(17):6587-94.
75. Claxton A, Baker LD, Hanson A, Trittschuh EH, 89. Han WN, Hölscher C, Yuan L, Yang W, Wang XH,
Cholerton B, Morgan A, Callaghan M, Arbuckle M, Wu MN, Qi JS. Liraglutide protects against amyloid-
Behl C, Craft S. Long-acting intranasal insulin beta protein-induced impairment of spatial learning
detemir improves cognition for adults with mild and memory in rats. Neurobiol Aging 2013;34(2):576-
cognitive impairment or early-stage Alzheimer's 88.
disease dementia. J Alzheimers Dis 2015;44(3):897- 90. Parthsarathy V, Holscher C. Chronic treatment with
906. the GLP1 analogue liraglutide increases cell
76. Craft S, Baker LD, Montine TJ, Minoshima S, Watson proliferation and differentiation into neurons in an AD
356 @Real Academia Nacional de Farmacia. Spain
